Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 5/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6596144 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TMEM97RAB9ALMNAKMT2A | |
| Acetic Acid SCHEMBL7844892 | 0.90 | SIGMAR1 (0.41) | SIGMAR1TMEM97RAB9ALMNAKMT2A | |
| Acetic Acid SCHEMBL7844895 | 0.90 | SIGMAR1 (0.41) | SIGMAR1TMEM97RAB9ALMNAKMT2A | |
| SCHEMBL3186276 | 0.80 | VNN1 (0.39) | RAB9ALMNAKMT2ASMN1; SMN2VNN1 | |
| SCHEMBL3186266 | 0.80 | VNN1 (0.39) | RAB9ALMNAKMT2ASMN1; SMN2VNN1 | |
| SCHEMBL5379828 | 0.79 | RAB9A (0.59) | SIGMAR1TMEM97RAB9ALMNAKMT2A | |
| SCHEMBL5219714 | 0.78 | RAB9A (0.38) | SIGMAR1TMEM97RAB9ALMNAKMT2A | |
| SCHEMBL5219709 | 0.78 | RAB9A (0.38) | SIGMAR1TMEM97RAB9ALMNAKMT2A | |
| SCHEMBL6592342 | 0.76 | RAB9A (0.63) | SIGMAR1TMEM97RAB9ALMNAKMT2A | |
| SCHEMBL6592336 | 0.76 | RAB9A (0.63) | SIGMAR1TMEM97RAB9ALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1157025-B1 | PYRAZOLOPYRIDINES | GLAXO GROUP LTD (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1311507-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-21 | — | — | EP | disclosed |
| US-6498166-B1 | POTENT AND SELECTIVE INHIBITORS OF CYCLOOXYGENASE-2; TREATING PAIN, FEVER AND INFLAMMATION | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| EP-1157025-A1 | PYRAZOLOPYRIDINES | GLAXO GROUP LIMITED (GB) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000052008-A1 | PYRAZOLOPYRIDINES | GLAXO GROUP LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | SIGMAR1 2720/4885TMEM97 2785/4885RAB9A 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.